|
Velasco-Durantez V, Cruz-Castellanos P, Hernandez R, Rodriguez-Gonzalez A, Fernandez Montes A, Gallego A, Manzano-Fernandez A, Sorribes E, Zafra M, Carmona-Bayonas A, Calderon C, Jimenez-Fonseca P. Prospective study of predictors for anxiety, depression, and somatization in a sample of 1807 cancer patients. Sci Rep. 2024 Feb 7;14(1):3188. doi: 10.1038/s41598-024-53212-y. PubMed PMID: 38326426; PubMed Central PMCID: PMC10850144.
AÑO: 2024; IF: 3.8
|
38326426
|
Pacheco-Barcia V, Custodio-Cabello S, Carrasco-Valero F, Palka-Kotlowska M, Marino-Mendez A, Carmona-Bayonas A, Gallego J, Martin AJM, Jimenez-Fonseca P, Cabezon-Gutierrez L. Systemic Inflammation Response Index and weight loss as prognostic factors in metastatic pancreatic cancer: A concept study from the PANTHEIA-SEOM trial. World J Gastrointest Oncol. 2024 Feb 15;16(2):386-397. doi: 10.4251/wjgo.v16.i2.386. PubMed PMID: 38425396; PubMed Central PMCID: PMC10900150.
AÑO: 2024; IF: 2.5
|
|
Rivera F, Longo F, Martin Richard M, Richart P, Alsina M, Carmona A, Custodio AB, Fernandez Montes A, Gallego J, Fleitas Kanonnikoff T. SEOM-GEMCAD-TTD clinical guideline for the diagnosis and treatment of gastric cancer (2023). Clin Transl Oncol. 2024 Nov;26(11):2826-2840. doi: 10.1007/s12094-024-03600-7. Epub 2024 Jul 18. PubMed PMID: 39023829; PubMed Central PMCID: PMC11467061.
AÑO: 2024; IF: 2.8
|
|
Rodriguez-Gonzalez A, Carmona-Bayonas A, Hernandez San Gil R, Cruz-Castellanos P, Antonanzas-Basa M, Lorente-Estelles D, Corral MJ, Gonzalez-Moya M, Castillo-Trujillo OA, Esteban E, Jimenez-Fonseca P, Calderon C. Impact of systemic cancer treatment on quality of life and mental well-being: a comparative analysis of patients with localized and advanced cancer. Clin Transl Oncol. 2023 Dec;25(12):3492-3500. doi: 10.1007/s12094-023-03214-5. Epub 2023 May 29. PubMed PMID: 37247131.
AÑO: 2023; IF: 2.8
|
|
Valcarcel S, Gallego J, Jimenez-Fonseca P, Diez M, de Castro EM, Hernandez R, Arrazubi V, Custodio A, Cano JM, Montes AF, Macias I, Visa L, Calvo A, Tocino RV, Lago NM, Limon ML, Granja M, Gil M, Pimentel P, Macia-Rivas L, Perez CH, Mangas M, Carnicero AM, Cerda P, Gonzalez LG, Navalon FG, Rambla MDM, Richard MM, Carmona-Bayonas A. Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry. J Cancer Res Clin Oncol. 2023 Jul;149(7):4077-4089. doi: 10.1007/s00432-022-04294-6. Epub 2022 Aug 30. PubMed PMID: 36042046.
AÑO: 2023; IF: 2.7
|